Opinion What’s Ahead for Teva? Four Threats, but No Funeral

The giant drugmaker is in a difficult situation, but not a fatal one. What it needs is a new CEO and it’s a pity the board has spent so much time looking for one

comments Print
UPDATE: Teva Names Lundbeck's K re Schultz as CEO